Biotech company Cytiva has set up a 30,000 sq ft facility in Bengaluru. The centre will help biopharma companies in India and across Asia-Pacific shorten development timelines, reduce manufacturing risk, and scale as India aims to grow its bioeconomy to $300 billion by 2030.
The facility is designed for single-use bioreactor that can scale up to 200 L and can produce toxicity batch material to support preclinical stages.
Pierre-Alain Ruffieux, Chief Operating Officer, Cytiva, said: “India’s scientific strength plays a vital role in global biopharma, and this facility reinforces that momentum. By expanding our capabilities here, we’re giving customers the infrastructure to move from idea to impact with greater speed, reliability, and excellence.”
Manoj Panicker, General Manager, Cytiva South Asia, said: “This facility will enable our customers to innovate faster while maintaining complete control of their processes, improving access to life-saving medicines. This is especially critical for rare diseases, emerging modalities, and the growing biosimilars market, where speed and flexibility are essential.”
Published on February 25, 2026
